Novel NGS-based Proteomics Revolutionizes Biomarker Identification in Liquid Biopsies
|
Sarantis Chlamydas Olink Proteomics, Sweden |
Abstract
Olink Proteomics is a globally present Swedish company, that enables high-plex protein biomarker discovery and development. Olink’s platform technology currently has the ability to robustly measure ~3,000 analytes. It’s been used in different settings due to its scalability and actionability such as in the elucidation of pathways and mechanisms of drug action, as a screening tools for identifying signatures/biomarkers with a prognostic/predictive significance as well as to safety and toxicity studies, drug target selection and differentiation. Due to the fact that the protein library, which continuously expands, covers all major biological pathways the applications are in numerous disease areas, such as Immuno-oncology, Neurology, Cardiology, Diabetes and Rare Diseases.
In this scientific talk we will go through a series of case studies elucidating the power of the Proximity-Extension Assay (PEA) capabilities.
As a general overview:
• We will discuss advantages, coverage, matrices that can be analyzed with this technology.
• How Olink PEA-technology enables biomarker identification, precision medicine and multiOmics approaches.
• Olink technology in drug discovery and disease areas research projects.
| Back to GQ2023 session page | Back to GQ2023 overview page |
